Health + Tech - Bioverge

Health + Tech, Investing, Startups

Volumetric to be acquired by 3D Systems ($DDD) in a deal worth up to $400M

Congratulations to the Volumetric team on their acquisition by 3D Systems!

Health + Tech, Investing, Startups

✨ New Investment Opportunity: Transforming Epilepsy Care 🙇

Invest in Eysz to accelerate personalized treatments with improved patient outcomes for 70M+ epilepsy patients worldwide.

Health + Tech, Investing, Startups

Congratulations, Echo!

Congratulations to our portfolio company Echo on their acquisition by CELLINK!

Health + Tech, Investing, Media

Why I Founded Bioverge: My Mission to Democratize Healthcare Investment Opportunities

Watch our CEO, Neil Littman, share the story that inspired him to found Bioverge.

Health + Tech, Investing, Press

Investment Opportunity, You Can Now Invest In Bioverge!

The Bioverge Reg CF Offering is Officially Live 🎊 and Accepting Investments!

Reimagining Artificial Organs: IVIVA Medical

Even in our modern age of medical miracles, the prognosis and treatments for end-stage organ failure are still woefully inadequate. IVIVA Medical is on course to change all that.

How Octagon is Revolutionizing Autoimmune Treatment

Over 23 million Americans suffer from disorders that stem from their immune systems mistakenly attacking their own, healthy cells. Octagon offers revolutionary treatments for these autoimmune diseases without compromising healthy immune function.

Health + Tech, Startups

Advancing Treatments for ALS and Neurodegenerative Diseases

EnClear Therapies is developing device-based systems to reduce or stop the progression of neurodegenerative diseases by eliminating the toxic proteins that provoke these conditions.

Health + Tech, Startups

Repair Biotechnologies is Tackling Longevity

The desire to prolong life and youthful vigor has existed for centuries without uniformly tangible results. Repair Biotechnologies offers to transform this desire into a reality.

Health + Tech, Media, Startups

Ancilia Presentation and Q&A with CEO Alexandra Sakatos

Ancilia is a computational bio-platform company that engineers phage-resistant bacterial therapeutics utilizing CRISPR/Cas to treat microbiome-linked diseases including inflammatory bowel disease (IBD) and immunotherapy-associated colitis.